Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Maryam, Akrami"'
Autor:
Alfred Zippelius, Ping-Chih Ho, Rahul Roychoudhuri, Zhengtao Xiao, Yu-Ming Chuang, Yingxi Xu, Jhan-Jie Peng, Maryam Akrami
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/9cc4dede2fea43db8b406bdbd6b20211
Autor:
Marcel P. Trefny, Nicole Kirchhammer, Priska Auf der Maur, Marina Natoli, Dominic Schmid, Markus Germann, Laura Fernandez Rodriguez, Petra Herzig, Jonas Lötscher, Maryam Akrami, Jane C. Stinchcombe, Michal A. Stanczak, Andreas Zingg, Melanie Buchi, Julien Roux, Romina Marone, Leyla Don, Didier Lardinois, Mark Wiese, Lukas T. Jeker, Mohamed Bentires-Alj, Jérémie Rossy, Daniela S. Thommen, Gillian M. Griffiths, Heinz Läubli, Christoph Hess, Alfred Zippelius
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-21 (2023)
The efficacy of T-cell-based cancer immunotherapies can be compromised by T cell exhaustion. Here the authors develop a human ex vivo exhaustion model and, based on a CRISPR-Cas9 screen, identify SNX9 as a regulator of T cell exhaustion, showing that
Externí odkaz:
https://doaj.org/article/fdf4b11832574e5fbfe57578d57e0309
Autor:
Mohsen Nabi Meybodi, Neda Arbab Tafti, Vahid Ramezani, Mahsa Tavakolian Ardakani, Maryam Akrami, Ali mohammad Ranjbar Jamal abadi
Publikováno v:
Majallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd, Vol 28, Iss 10, Pp 3144-3152 (2020)
Introduction: Herbal medicines are one of the most widely used complementary therapies in the world. Therefore, it is necessary to perform exact studies on the status of herbal medicines in communities. The aim of this study was surveying the prescri
Externí odkaz:
https://doaj.org/article/7bf070705f1a49288dad43ef76c56a6f
Autor:
Mahsa Tavakolian Ardakani, Vahid Ramezani, Ali mohammad Ranjbar Jamal abadi, Mohsen Nabi Meybodi, Maryam Akrami, Neda Arbab Tafti
Publikováno v:
Majallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd, Vol 28, Iss 10, Pp 3144-3152 (2020)
Introduction: Herbal medicines are one of the most widely used complementary therapies in the world. Therefore, it is necessary to perform exact studies on the status of herbal medicines in communities. The aim of this study was surveying the prescri
Autor:
Hiroyuki Sato, Tasuku Honjo, Michio Tomura, Akiko Nishii, Sidonia Fagarasan, Kenji Chamoto, Michio Miyajima, Ryuji Suzuki, Rosemary J. Menzies, Maryam Akrami
Publikováno v:
Proceedings of the National Academy of Sciences. 117:23674-23683
The gut microbiome has garnered attention as an effective target to boost immunity and improve cancer immunotherapy. We found that B cell-defective (BCD) mice, such as µ-membrane targeted deletion (µMT) and activation-induced cytidine deaminase (AI
Autor:
Motahareh, Salarvand, Vahid, Ramezani, Fatemeh, Salarvand, Zeinab, Aref Darabi, Maryam, Akrami
Publikováno v:
Iranian journal of pharmaceutical research : IJPR. 20(2)
Aimed to improve the dissolution profile of risperidone and increase the compliance of psychotic patients, we designed a fast dissolution tablet (FDT) containing nanoparticles. Risperidone nanoparticles were prepared by the acid-alkali neutralization
Autor:
Reihaneh Radmanesh, Mohsen Nabi Meybodi, Vahid Ramezani, Maryam Akrami, Mohammad Ali Ranjbar, Azadeh Emami
Publikováno v:
Ufuq-i Dānish, Vol 26, Iss 1, Pp 82-93 (2019)
Aims: Any pharmaceutical product made in pharmacy, hospital or factory may be contaminated with microbes. This contamination can originate from raw materials or during production. Hence, it is important to study the physical and chemical properties a
Autor:
Maryam, Akrami, Rosemary, Menzies, Kenji, Chamoto, Michio, Miyajima, Ryuji, Suzuki, Hiroyuki, Sato, Akiko, Nishii, Michio, Tomura, Sidonia, Fagarasan, Tasuku, Honjo
Publikováno v:
Proc Natl Acad Sci U S A
The gut microbiome has garnered attention as an effective target to boost immunity and improve cancer immunotherapy. We found that B cell-defective (BCD) mice, such as µ-membrane targeted deletion (µMT) and activation-induced cytidine deaminase (AI
Autor:
Tasuku Honjo, Toyohiro Hirai, Yuichi Sakamori, Yasushi Okuno, Maryam Akrami, Fumihiko Matsuda, Ryusuke Hatae, Hiroaki Ozasa, Hironori Yoshida, Kazuhiro Sonomura, Kenji Chamoto, Kei Taneishi, Shuji Kawaguchi, Sidonia Fagarasan, Izuru Masuda, Young Hak Kim
Publikováno v:
JCI Insight. 5
BACKGROUND: Current clinical biomarkers for the programmed cell death 1 (PD-1) blockade therapy are insufficient because they rely only on the tumor properties, such as programmed cell death ligand 1 expression frequency and tumor mutation burden. Id
Autor:
Maryam, Akramisomeabozorg
0048
甲第22833号
医博第4672号
新制||医||1047(附属図書館)
学位規則第4条第1項該当
Doctor of Medical Science
Kyoto University
DFAM
甲第22833号
医博第4672号
新制||医||1047(附属図書館)
学位規則第4条第1項該当
Doctor of Medical Science
Kyoto University
DFAM
Externí odkaz:
http://hdl.handle.net/2433/259729